Bonnie Fendrock is a strategic and operational advisor to rapidly growing life science companies. Given her general management experience in both start-ups and high growth companies, she specializes in strategic development of technology, business plan development and execution, company positioning and pitch development for fund raising, partnership strategy and alliance management, and multi-functional team management. Her technology experience includes biotherapeutics, gene therapy, biological medical devices, bioengineered tools and chemistry-based delivery platforms.
Bonnie is currently incubating a new start-up, Cyta Therapeutics, a nanotherapeutics spin-out from University of Massachusetts, Amherst. Previously Bonnie was CEO and co-founder of Hepregen Corporation, a venture backed, commercial stage, MIT spin-out based on the bioengineered in vitro micro-liver platform developed by Professor Sangeeta Bhatia. In 2012, Bonnie was honored along with other innovation leaders as one of the Mass High Tech ‘Women to Watch’. Over her 30 year career in life sciences, Bonnie has held roles in corporate and business development, marketing and program management from foundational biotechnology companies including Genzyme, Somatix, Genetics Institute and Acusphere. Prior to business school, she worked in research and product development at Integrated Genetics and Centocor.
Bonnie has been a Director on the Boston Chapter Board of the Healthcare Businesswomen’s Association (HBA) for five years and has mentored entrepreneurs through MassConnect, MassChallenge, and The Deshpande Center.
Bonnie holds an MBA from the Wharton School, University of Pennsylvania as a Management of Technology Fellow, an MS in Interdisciplinary Science from MIT, and a BA in Molecular Biology from Wellesley College. She recently completed the Women on Boards program at the Harvard T. Chan of Public Health.